Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Nature. 2023 Jul;619(7971):851-859. doi: 10.1038/s41586-023-06253-8. Epub 2023 Jul 19.
Lung cancer is the leading cause of cancer deaths worldwide. Mutations in the tumour suppressor gene TP53 occur in 50% of lung adenocarcinomas (LUADs) and are linked to poor prognosis, but how p53 suppresses LUAD development remains enigmatic. We show here that p53 suppresses LUAD by governing cell state, specifically by promoting alveolar type 1 (AT1) differentiation. Using mice that express oncogenic Kras and null, wild-type or hypermorphic Trp53 alleles in alveolar type 2 (AT2) cells, we observed graded effects of p53 on LUAD initiation and progression. RNA sequencing and ATAC sequencing of LUAD cells uncovered a p53-induced AT1 differentiation programme during tumour suppression in vivo through direct DNA binding, chromatin remodelling and induction of genes characteristic of AT1 cells. Single-cell transcriptomics analyses revealed that during LUAD evolution, p53 promotes AT1 differentiation through action in a transitional cell state analogous to a transient intermediary seen during AT2-to-AT1 cell differentiation in alveolar injury repair. Notably, p53 inactivation results in the inappropriate persistence of these transitional cancer cells accompanied by upregulated growth signalling and divergence from lung lineage identity, characteristics associated with LUAD progression. Analysis of Trp53 wild-type and Trp53-null mice showed that p53 also directs alveolar regeneration after injury by regulating AT2 cell self-renewal and promoting transitional cell differentiation into AT1 cells. Collectively, these findings illuminate mechanisms of p53-mediated LUAD suppression, in which p53 governs alveolar differentiation, and suggest that tumour suppression reflects a fundamental role of p53 in orchestrating tissue repair after injury.
肺癌是全球癌症死亡的主要原因。肿瘤抑制基因 TP53 的突变发生在 50%的肺腺癌 (LUAD) 中,并与预后不良相关,但 p53 如何抑制 LUAD 发展仍然是个谜。我们在这里表明,p53 通过调节细胞状态来抑制 LUAD 的发生,特别是通过促进肺泡 1 型 (AT1) 分化。我们使用在肺泡 2 型 (AT2) 细胞中表达致癌性 Kras 和缺失、野生型或超突变 Trp53 等位基因的小鼠,观察到 p53 对 LUAD 起始和进展的分级作用。对 LUAD 细胞的 RNA 测序和 ATAC 测序揭示了 p53 在体内通过直接 DNA 结合、染色质重塑和诱导 AT1 细胞特征基因,在肿瘤抑制过程中诱导的 AT1 分化程序。单细胞转录组学分析表明,在 LUAD 进化过程中,p53 通过在类似于肺泡损伤修复过程中 AT2 到 AT1 细胞分化中短暂出现的过渡细胞状态中的作用,促进 AT1 分化。值得注意的是,p53 失活导致这些过渡性癌细胞的不当持续存在,同时伴有上调的生长信号和与 LUAD 进展相关的肺谱系身份的分化。对 Trp53 野生型和 Trp53 缺失型小鼠的分析表明,p53 还通过调节 AT2 细胞自我更新和促进过渡性细胞分化为 AT1 细胞,指导损伤后的肺泡再生。总的来说,这些发现阐明了 p53 介导的 LUAD 抑制的机制,其中 p53 调节肺泡分化,并表明肿瘤抑制反映了 p53 在组织损伤后协调组织修复的基本作用。